Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Company Deals

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib

Fineline Cube Apr 22, 2026
Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Fineline Cube Apr 22, 2026
Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Fineline Cube Apr 22, 2026
Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Fineline Cube Apr 22, 2026
Company Drug

Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09

Fineline Cube Jun 15, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...

Company Drug

Mabwell Bioscience’s IL-11 mAb 9MW3811 Receives US FDA Clinical Trial Approval

Fineline Cube Jun 15, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Policy / Regulatory

NHSA Report Highlights ‘Flying Inspections’ Impact on Medical Insurance Fund Use in 2022

Fineline Cube Jun 14, 2023

The National Healthcare Security Administration (NHSA) has released a report outlining the outcomes of ‘flying...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HIF-2α Inhibitor HS-10516 Clinical Study

Fineline Cube Jun 14, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received approval...

Company Deals

Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China

Fineline Cube Jun 14, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has...

Company

UIH Surgical to Invest RMB 2.5 Billion in Wuhan Medical Innovation and Robotics Base

Fineline Cube Jun 14, 2023

United Imaging Healthcare Technology Co., Ltd (UIH), through its subsidiary UIH Surgical, has announced plans...

Company Deals Medical Device

JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion

Fineline Cube Jun 14, 2023

China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai...

Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Company Drug

Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study

Fineline Cube Jun 14, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...

Company Drug

Croma-Pharma Initiates Phase III Clinical Trial in China for Hyaluronic Acid Dermal Filler

Fineline Cube Jun 13, 2023

Austria-based Croma-Pharma has revealed that the first patient is set to be enrolled in a...

Company Deals R&D

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

Fineline Cube Jun 13, 2023

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...

Company Deals

Apeloa Pharmaceutical Partners with Zelgen Biopharmaceuticals for CDMO Programs

Fineline Cube Jun 13, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Drug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

Fineline Cube Jun 13, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...

Company Drug

Bio-Thera Solutions’ BAT6026 Receives NMPA Approval for Atopic Dermatitis Clinical Trials

Fineline Cube Jun 13, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced receiving approval from China’s National Medical Products...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...

Company Drug

CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study

Fineline Cube Jun 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Deals

VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities

Fineline Cube Jun 13, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...

Company Drug

China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures

Fineline Cube Jun 13, 2023

China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML

Fineline Cube Jun 13, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China

Fineline Cube Jun 13, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...

Posts pagination

1 … 504 505 506 … 655

Recent updates

  • Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
  • Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M
  • Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials
  • Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
  • Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.